Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross PI3K Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.592

    Phosphoinositide 3-kinase (PI3K) Inhibitors

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.592 alerts

    Get alerted when Policy 5.01.592 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy establishes medical-necessity and prior-authorization criteria for selected PI3K, AKT, and related pathway inhibitors used for specified cancers, activated PI3K delta syndrome, and PIK3CA-related overgrowth spectrum. Oral drugs are managed through the pharmacy benefit.

    Policy Summary
    PayerPremera Bluecross
    PolicyPhosphoinositide 3-kinase (PI3K) Inhibitors
    Policy CodePolicy 5.01.592
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit office visit notes documenting the diagnosis, relevant history, physical evaluation, and medication history for coverage review.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Itovebi (inavolisib).

    Added Truqap (capivasertib) coverage criteria for certain individuals with breast cancer and metastatic PTEN-deficient prostate cancer.

    Added Joenja (leniolisib) coverage criteria for activated phosphoinositide 3-kinase delta syndrome.

    Added coverage for Vijoice and Piqray for PIK3CA-related overgrowth spectrum and revised Piqray breast cancer criteria.

    Changed initial authorization for all other reviews of listed oral drugs from 3 months to 6 months.

    Removed coverage for Ukoniq, Aliqopa, duvelisib in relapsed or refractory follicular lymphoma, and selected idelalisib and copanlisib indications.

    Removed HCPCS code J9057.

    7

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PI3K-pathway drugs with policy criteria
    6 monthsMaximum initial authorization
    12 monthsMaximum reauthorization
    Pharmacy benefitOral drug benefit management
    300 mg dailyPiqray breast cancer dose limit

    Drug-Specific Coverage Criteria

    Copiktra initial therapy

    Covered when all of the following are met:

    Copiktra for relapsed or refractory CLL/SLL

    • Eligibility

      • The individual has relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
      • The individual is aged 18 years or older.Age >=18 years
      • The individual has had at least two prior systemic therapies.>=2 prior systemic therapies

    Itovebi initial therapy

    Covered when all of the following are met:

    Itovebi for HR-positive, HER2-negative PIK3CA-mutated breast cancer

    • The individual is aged 18 years or older.Age >=18 years
    • The individual has endocrine-resistant, HR-positive, HER2-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation.
    • Disease-treatment history

      • The individual has experienced disease progression following at least one line of endocrine therapy in the metastatic setting.
      • The individual has experienced recurrence on or within 12 months of completing adjuvant therapy.
    • Itovebi will be given in combination with Ibrance (palbociclib) and fulvestrant as first-line therapy.

    Joenja initial therapy

    Covered when all of the following are met:

    Joenja for APDS

    • The individual is aged 12 years or older.Age >=12 years
    • The individual is diagnosed with activated phosphoinositide 3-kinase delta syndrome (APDS).
    • The individual has a documented APDS-associated PI3K delta gene mutation with a documented variant in either PIK3CD or PIK3R1.
    • Joenja is prescribed by or in consultation with an oncologist, medical geneticist, or hematologist.
    • The dose is limited to 140 mg per day, taken as 70 mg twice daily.140 mg/day; 70 mg twice daily

    Piqray for breast cancer

    Covered when all of the following are met:

    • The individual is aged 18 years or older.Age >=18 years
    • The individual has HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test.
    • The individual has experienced progression on or after an endocrine-based regimen.
    • Piqray will be used in combination with fulvestrant.
    • The dose is limited to 300 mg once daily.300 mg once daily

    Piqray for PROS

    Covered when all of the following are met:

    Piqray for PIK3CA-related overgrowth spectrum (PROS)

    • The individual is aged 18 years or older.Age >=18 years
    • The individual is diagnosed with PIK3CA-related overgrowth spectrum (PROS).
    • The individual has at least one target lesion identified on imaging.At least one imaging-identified target lesion
    • The individual has a documented PIK3CA gene mutation.
    • Piqray is prescribed by or in consultation with an oncologist, geneticist, or hematologist.

    Truqap for prostate cancer

    Covered when all of the following are met:

    Truqap for metastatic prostate cancer

    • The individual is aged 18 years or older.Age >=18 years
    • The individual has metastatic androgen pathway modulation-naive or sensitive prostate cancer.
    • The individual is PTEN-deficient.
    • Required combination therapy

      • Truqap is used in combination with abiraterone.

    Truqap for breast cancer

    Covered when all of the following are met:

    Truqap for HR-positive, HER2-negative breast cancer

    • The individual is aged 18 years or older.Age >=18 years
    • The individual has HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations.
    • Disease-treatment history

      • The individual has experienced disease progression following at least one line of endocrine therapy in the metastatic setting.
      • The individual has experienced recurrence on or within 12 months of completing adjuvant therapy.

    Vijoice initial therapy

    Covered when all of the following are met:

    Vijoice for PIK3CA-related overgrowth spectrum (PROS)

    • The individual is aged 2 years or older.Age >=2 years
    • The individual is diagnosed with PIK3CA-related overgrowth spectrum (PROS).
    • The individual has at least one target lesion identified on imaging.At least one imaging-identified target lesion
    • Vijoice is prescribed by or in consultation with an oncologist, geneticist, or hematologist.

    Zydelig initial therapy

    Covered when all of the following are met:

    Zydelig for relapsed CLL

    • The individual has relapsed chronic lymphocytic leukemia (CLL).
    • Zydelig is used in combination with rituximab for an individual for whom rituximab alone would be considered appropriate therapy because of other comorbidities.
    • The dose is limited to 300 mg per day, taken as 150 mg twice daily.300 mg/day; 150 mg twice daily

      Zydelig is not indicated or recommended for first-line treatment of any individual.

    Use of medications in this policy for conditions not specifically outlined is considered investigational and is not eligible for coverage under these criteria. The medications are also subject to the applicable U.S. Food and Drug Administration (FDA) dosage and administration prescribing information.

    Zydelig (idelalisib) is not indicated and is not recommended for first-line treatment of any individual. Coverage is limited to the policy’s specified relapsed chronic lymphocytic leukemia use in combination with rituximab when rituximab alone would otherwise be appropriate because of comorbidities.

    Coverage for Aliqopa (copanlisib) in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was removed. Copanlisib is not FDA approved for CLL or SLL, and the cited NCCN Guidelines do not list or recommend its use for these conditions.

    Coverage for Copiktra (duvelisib) in relapsed or refractory follicular lymphoma was removed after the manufacturer voluntarily withdrew the indication. The indication had received accelerated approval contingent on an additional confirmatory trial; the manufacturer elected not to pursue that trial and voluntarily withdrew the indication.

    Coverage criteria for Zydelig (idelalisib) in certain follicular lymphoma or small lymphocytic lymphoma uses were removed because use for this indication was removed from the prescribing information. The current criteria therefore address the specified relapsed CLL use rather than these historical indications.

    Authorization Period

    Initial authorization period

    Initial authorization may be approved when the following criterion is met:

    Initial authorization

    • The requested drug meets its applicable drug-specific coverage criteria and the use is an indication outlined in this policy.Authorization up to 6 months

    Reauthorization Requirements

    All covered drugs: reauthorization

    Reauthorization may be approved when all of the following are met:

    Continuation of therapy

    • The applicable drug-specific coverage criteria remain met.
    • Chart notes demonstrate that the individual continues to show a positive clinical response to therapy.
    • For Piqray used for PROS and for Vijoice, the response includes a reduction from baseline in the sum of measurable target-lesion volume.

      Required response documentation for these indications.

    Prior Treatment and Sequencing

    StepMedication and indicationRequired treatment sequence
    1Itovebi (inavolisib) for endocrine-resistant PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancerUse in combination with Ibrance (palbociclib) and fulvestrant as first-line metastatic therapy. The individual must have disease progression after at least one line of endocrine therapy in the metastatic setting, or recurrence on or within 12 months of completing adjuvant therapy.
    StepMedication and indicationRequired treatment sequence
    1Piqray (alpelisib) for HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancerUse in combination with fulvestrant after progression on or after an endocrine-based regimen.
    StepMedication and indicationRequired treatment sequence
    1Truqap (capivasertib) for HR-positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA, AKT1, or PTEN alterationUse in combination with fulvestrant after progression following at least one line of endocrine therapy in the metastatic setting, or recurrence on or within 12 months of completing adjuvant therapy. The individual must not have progressed on or following another PI3K/AKT/PTEN inhibitor and must either have tried Piqray with intolerance but without disease progression, or have a specific solitary AKT1 or PTEN mutation not sensitive to Piqray.
    StepMedication and indicationRequired treatment sequence
    1Copiktra (duvelisib) for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)The individual must have received at least two prior systemic therapies.

    Dose and Quantity Limits

    Quantity limit
    MedicationItovebi (inavolisib)
    Daily dose9 mg once daily
    Applicable contextEndocrine-resistant PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer
    Quantity limit
    MedicationJoenja (leniolisib)
    Daily dose140 mg per day
    AdministrationTaken as 70 mg twice daily

    Coding Information

    Removed/Historical HCPCS CodesHCPCS
    J9057New HCPCS code effective 1/1/19; subsequently removed from the policy.
    J9999HCPCS code removed on 1/1/19.

    Authorization and Submission Requirements

    Prior Authorization

    Authorization Duration and Renewal Review

    Submit for authorization review with documentation that the applicable drug-specific medical-necessity criteria are met. Initial authorization may be approved for up to 6 months; reauthorization may be approved for up to 12 months when the drug-specific criteria remain met and required response documentation is provided.

    • Initial authorization: all drugs in this policy may be approved for up to 6 months.
    • Reauthorization: Copiktra, Itovebi, Joenja, Piqray for breast cancer, Truqap, and Zydelig may be approved for up to 12 months when criteria remain met and chart notes demonstrate a continued positive clinical response.
    • Reauthorization: Piqray for PROS and Vijoice may be approved for up to 12 months when criteria remain met and chart notes document a reduction from baseline in the sum of measurable target-lesion volume.
    Billing Rule

    Clinical Background

    PI3K inhibitors block one or more enzymes in an intracellular signaling pathway involved in cell growth, helping turn down signals that promote cellular proliferation. This policy addresses selected uses of PI3K, AKT, and related pathway inhibitors in hematologic malignancies, breast cancer, prostate cancer, activated PI3K delta syndrome, and PIK3CA-related overgrowth spectrum.

    Definitions

    HER2-negative
    HER2 expression0 or 1+ intensity on immunohistochemical testing
    HER2 equivocal result2+ intensity on immunohistochemical testing
    Required confirmation for 2+ resultNo amplification on in situ hybridization
    Age limits
    Basis for age limitsApplicable US Food and Drug Administration (FDA)-approved indications
    Policy applicationAge limits specified in the policy follow the applicable FDA-approved indications
    ScopeThe determination applies where FDA-approved indications are applicable
    Policy Summary
    PayerPremera Bluecross
    PolicyPhosphoinositide 3-kinase (PI3K) Inhibitors
    Policy CodePolicy 5.01.592
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit office visit notes documenting the diagnosis, relevant history, physical evaluation, and medication history for coverage review.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaAuthorization PeriodReauthorization RequirementsPrior Treatment and SequencingDose and Quantity LimitsCoding InformationAuthorization and Submission RequirementsClinical BackgroundDefinitions
    The individual has not experienced disease progression on or following another PI3K inhibitor.
  1. Itovebi is prescribed by or in consultation with an oncologist.
  2. The dose is limited to 9 mg once daily.9 mg once daily
  3. The dose is limited to 250 mg once daily.250 mg once daily
  4. Truqap is used in combination with prednisone.
  5. Truqap is used with androgen deprivation therapy (ADT), documented by concurrent receipt of a gonadotropin-releasing hormone (GnRH) analog or prior bilateral orchiectomy.
  6. The dose is limited to 400 mg twice daily for 4 days followed by 3 days off.400 mg twice daily for 4 days, then 3 days off
  7. Truqap will be used in combination with fulvestrant.
  8. The individual has not experienced disease progression on or following another PI3K/AKT/PTEN inhibitor, such as Piqray.
  9. Piqray-related qualifying pathway

    • The individual has tried Piqray and had intolerance without disease progression.
    • The individual has a specific solitary AKT1 or PTEN mutation not sensitive to Piqray.
  10. The dose is limited to 400 mg twice daily for 4 days followed by 3 days off.400 mg twice daily for 4 days, then 3 days off
  11. The dose is limited according to age: 50 mg once daily for individuals aged 2–5 years; 125 mg once daily for individuals aged 6–17 years; or 250 mg once daily for individuals aged 18 years and older.
    Age 2–5: 50 mg once daily; age 6–17: 125 mg once daily; age >=18: 250 mg once daily
    Quantity limit
    MedicationPiqray (alpelisib)
    Daily dose300 mg once daily
    Applicable contextHR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer
    Quantity limit
    MedicationPiqray (alpelisib)
    Daily dose250 mg once daily
    Applicable contextPIK3CA-related overgrowth spectrum (PROS) in individuals aged 18 years or older
    Quantity limit
    MedicationTruqap (capivasertib)
    Dose schedule400 mg twice daily for 4 days followed by 3 days off
    Applicable contextAdult individuals with metastatic androgen pathway modulation-naive or sensitive, PTEN-deficient prostate cancer
    Quantity limit
    MedicationTruqap (capivasertib)
    Dose schedule400 mg twice daily for 4 days followed by 3 days off
    Applicable contextAdult individuals with HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA, AKT1, or PTEN alterations
    Quantity limits by age
    Age 2–5 years50 mg once daily
    Age 6–17 years125 mg once daily
    Age 18 years and older250 mg once daily
    Quantity limit
    MedicationZydelig (idelalisib)
    Daily dose300 mg per day
    AdministrationTaken as 150 mg twice daily
    Quantity limit
    MedicationPiqray (alpelisib)
    Daily dose300 mg once daily
    Policy contextBreast cancer treatment in combination with fulvestrant; the dose limit was added to the policy criteria in the 2026 update

    Pharmacy Benefit Management

    The following orally administered drugs are managed through the pharmacy benefit: Copiktra, Itovebi, Joenja, Piqray, Truqap, and Zydelig.

    Documentation Required

    Required Clinical Records

    Submit medical records demonstrating that the applicable medical-necessity criteria are met. Records must include office-visit documentation with the diagnosis, relevant history, physical evaluation, and medication history.

    • Include supporting medical records for all conditions reviewed.
    • CPT codes, descriptions, and materials are copyrighted by the American Medical Association (AMA); HCPCS codes, descriptions, and materials are copyrighted by the Centers for Medicare & Medicaid Services (CMS).
    Documentation Required

    Continuation Response Documentation

    For reauthorization, submit chart notes showing that the individual continues to have a positive clinical response to therapy. For Piqray used for PROS and Vijoice, document a reduction from baseline in the sum of measurable target-lesion volume.

    • Response documentation applies to reviews for Copiktra, Itovebi, Joenja, Piqray for breast cancer, Truqap, and Zydelig.
    • For Piqray for PROS and Vijoice, include imaging or other chart-note documentation showing reduction in the sum of measurable target-lesion volume from baseline.
    Denial Risk

    Unlisted Indications

    Uses of drugs in this policy for conditions not outlined in the policy are considered investigational.

    • Coverage is subject to the applicable product’s United States Food and Drug Administration (FDA) dosage and administration prescribing information.

    Unsupported block type: denial_risk

    Step Therapy

    Truqap Sequencing Requirement

    For Truqap treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer, document the required sequencing and prior-treatment conditions before requesting authorization.

    • The individual must not have experienced disease progression on or following another PI3K/AKT/PTEN inhibitor, such as Piqray.
    • The individual must have either tried Piqray and experienced intolerance without disease progression, or have a specific solitary AKT1 or PTEN mutation that is not sensitive to Piqray.
    Prior Authorization

    Drug-Specific Medical-Necessity Criteria

    Document the diagnosis, patient-specific clinical criteria, required molecular findings or prior treatment, combination therapy, prescriber qualifications, and dose limits for the requested drug.

    • Copiktra (duvelisib): Relapsed or refractory CLL or SLL; age 18 years or older; at least two prior systemic therapies.
    • Itovebi (inavolisib): Adult with endocrine-resistant, HR-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer; progression after at least one line of endocrine therapy in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy; used with Ibrance (palbociclib) and fulvestrant as first-line therapy; no progression on or following another PI3K inhibitor; prescribed by or in consultation with an oncologist; dose limited to 9 mg once daily.
    • Joenja (leniolisib): Age 12 years or older; diagnosed with activated PI3K delta syndrome (APDS); documented APDS-associated PI3K delta gene mutation with a documented variant in PIK3CD or PIK3R1; prescribed by or in consultation with an oncologist, medical geneticist, or hematologist; dose limited to 140 mg/day (70 mg twice daily).
    • Piqray (alpelisib) for breast cancer: Age 18 years or older; HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer detected by an FDA-approved test; progression on or after an endocrine-based regimen; used with fulvestrant; dose limited to 300 mg once daily.
    • Piqray for PROS: Age 18 years or older; diagnosed with PIK3CA-related overgrowth spectrum (PROS); at least one target lesion identified on imaging; documented PIK3CA mutation; prescribed by or in consultation with an oncologist, geneticist, or hematologist; dose limited to 250 mg once daily.
    • Truqap (capivasertib) for prostate cancer: Age 18 years or older; metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer; PTEN-deficient; used with abiraterone, prednisone, and androgen-deprivation therapy documented by concurrent GnRH analog use or prior bilateral orchiectomy; dose limited to 400 mg twice daily for 4 days followed by 3 days off.
    • Truqap for breast cancer: Age 18 years or older; HR-positive, HER2-negative locally advanced or metastatic breast cancer; one or more PIK3CA, AKT1, or PTEN alterations; progression after at least one line of endocrine therapy in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy; used with fulvestrant; meets the required Piqray sequencing condition; dose limited to 400 mg twice daily for 4 days followed by 3 days off. HER2-negative means 0 or 1+ intensity by immunohistochemistry, or 2+ intensity with no amplification by in situ hybridization.
    • Vijoice (alpelisib): Age 2 years or older; diagnosed with PROS; at least one target lesion identified on imaging; prescribed by or in consultation with an oncologist, geneticist, or hematologist. Dose is limited to 50 mg once daily for ages 2–5, 125 mg once daily for ages 6–17, and 250 mg once daily for ages 18 and older.
    • Zydelig (idelalisib): Relapsed CLL treated in combination with rituximab when rituximab alone would otherwise be appropriate because of comorbidities; dose limited to 300 mg/day (150 mg twice daily).
    PI3K inhibitor
    TargetOne or more enzymes in an important intracellular cell-signaling pathway
    MechanismBlocks the enzymes in the signaling pathway
    Intended effectTurns cell growth to the off position
    Activated phosphoinositide 3-kinase delta syndrome (APDS)
    ConditionActivated phosphoinositide 3-kinase delta syndrome (APDS)
    Underlying abnormalityActivating PI3K-delta pathway abnormalities
    Genetic confirmationA documented variant in either PIK3CD or PIK3R1 is required in the cited study context
    PIK3CA-related overgrowth spectrum (PROS)
    ConditionPIK3CA-related overgrowth spectrum (PROS)
    Disorder groupA heterogeneous group of disorders
    Clinical featuresAssociated with vascular malformations and segmental overgrowth, with early-onset progressive symptoms